talazoparib tosylate

{
  "id": "MLC-T-ONC-008504",
  "term": "talazoparib tosylate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone to treat adults with HER2-negative breast cancer that has spread and has certain mutations (changes) in the BRCA1 or BRCA2 gene and with enzalutamide to treat adults with prostate cancer that has spread, has not responded to treatments that lower testosterone levels, and has a mutation in the HRR gene. It is also being studied in the treatment of other types of cancer. Talazoparib tosylate blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Talazoparib tosylate is a type of PARP inhibitor. Also called Talzenna.",
    "The tosylate salt form of talazoparib, an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks."
  ],
  "synonyms": [
    "Talzenna",
    "PARP inhibitor BMN-673"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/talazoparib-tosylate/"
}